biostudies-literatureUnknown13Yang S<b>Background:</b> This study aimed to confirm the role of enhancer RNAs (eRNAs) in gastric cancer and their clinical utility. <b>Methods:</b> We used Cox survival and relevance analysis to identify the candidate eRNAs in gastric cancer and performed Gene Ontology and Reactome pathway enrichment to determine the potential functions of eRNAs. Correlation between eRNA, tumor-infiltrating immune cells, and drug sensitivity was then analyzed. <b>Results:</b> <i>CDK6-AS1</i>, a long non-coding RNA cyclin-dependent kinase 6, may serve as a poor potential prognostic biomarker candidate in gastric cancer with a positive correlation with its target gene <i>CDK6</i>. The low <i>CDK6-AS1</i> expression group showed more frequent mutated driver genes than the high expression group. Moreover, <i>CDK6-AS1</i> is involved in a key oncogenic pathway of the cell cycle and RNA transcription. <i>CDK6-AS1</i> also shows dysregulations and associations with prognosis at the pan-cancer level. This eRNA may also be associated with immune cell infiltration and drug sensitivity. <b>Conclusion:</b> <i>CDK6-AS1</i> may be a potential prognostic biomarker and chemotherapeutic drug sensitivity predictor in gastric cancer.Frontiers in genetics854211https://www.ebi.ac.uk/biostudies/studies/S-EPMC9100412biostudies-literatureIdentification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer.PMC9100412Zou XYang HLi JLi CZhu LMa ZZhang LYang SZhang AfalseIdentification of Enhancer RNA CDK6-AS1 as a Potential Novel Prognostic Biomarker in Gastric Cancer.<b>Background:</b> This study aimed to confirm the role of enhancer RNAs (eRNAs) in gastric cancer and their clinical utility. <b>Methods:</b> We used Cox survival and relevance analysis to identify the candidate eRNAs in gastric cancer and performed Gene Ontology and Reactome pathway enrichment to determine the potential functions of eRNAs. Correlation between eRNA, tumor-infiltrating immune cells, and drug sensitivity was then analyzed. <b>Results:</b> <i>CDK6-AS1</i>, a long non-coding RNA cyclin-dependent kinase 6, may serve as a poor potential prognostic biomarker candidate in gastric cancer with a positive correlation with its target gene <i>CDK6</i>. The low <i>CDK6-AS1</i> expression group showed more frequent mutated driver genes than the high expression group. Moreover, <i>CDK6-AS1</i> is involved in a key oncogenic pathway of the cell cycle and RNA transcription. <i>CDK6-AS1</i> also shows dysregulations and associations with prognosis at the pan-cancer level. This eRNA may also be associated with immune cell infiltration and drug sensitivity. <b>Conclusion:</b> <i>CDK6-AS1</i> may be a potential prognostic biomarker and chemotherapeutic drug sensitivity predictor in gastric cancer.2022-01-01T00:00:00Z20222024-11-15T20:44:11.712Z2024-11-15T20:44:11.712ZS-EPMC91004123557104310.3389/fgene.2022.854211